Published in Clin Infect Dis on January 01, 2008
Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One (2009) 4.92
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol (2009) 1.43
Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One (2011) 1.42
Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annu Rev Med (2009) 1.24
Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem Biol (2011) 1.08
Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis (2012) 1.07
Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. BMC Infect Dis (2014) 1.04
The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol (2010) 1.03
Radiological findings of extensively drug-resistant pulmonary tuberculosis in non-AIDS adults: comparisons with findings of multidrug-resistant and drug-sensitive tuberculosis. Korean J Radiol (2009) 1.03
Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One (2013) 1.02
Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. J Am Chem Soc (2011) 1.00
Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother (2011) 0.96
Rates and risk factors for drug resistance tuberculosis in Northeastern China. BMC Public Health (2013) 0.96
Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med (2008) 0.96
Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One (2013) 0.94
Extensively drug-resistant tuberculosis, China. Emerg Infect Dis (2011) 0.93
Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect Immun (2010) 0.89
Clinical and genotypic characteristics of extensively drug-resistant and multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis (2010) 0.83
Evolution and transmission patterns of extensively drug-resistant tuberculosis in China. Antimicrob Agents Chemother (2014) 0.82
Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. Saudi Med J (2015) 0.81
Utility of the REBA MTB-Rifa® assay for rapid detection of rifampicin resistant Mycobacterium tuberculosis. BMC Infect Dis (2013) 0.78
Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China. BMC Infect Dis (2016) 0.75
Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China. BMC Infect Dis (2017) 0.75
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 8.17
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Phanerozoic trends in the global diversity of marine invertebrates. Science (2008) 5.36
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med (2009) 4.52
Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med (2003) 4.46
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med (2008) 4.33
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood (2011) 4.21
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis (2008) 3.84
Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med (2010) 3.83
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med (2010) 3.55
Age and the epidemiology and pathogenesis of tuberculosis. Lancet (2010) 3.37
DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36
Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29
Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension (2002) 3.23
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol (2009) 3.13
JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood (2009) 3.00
Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol (2006) 2.97
Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet (2004) 2.90
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89
Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med (2012) 2.87
Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med (2007) 2.85
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA (2004) 2.60
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol (2009) 2.58
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47
Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med (2012) 2.44
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37
Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) (2010) 2.33
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) (2010) 2.26
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
The hyper-IgE syndromes. Immunol Allergy Clin North Am (2008) 2.19
X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med (2006) 2.18
A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity (2011) 2.15
Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12
Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem (2003) 2.09
Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med (2012) 2.08
Parasite burden and severity of malaria in Tanzanian children. N Engl J Med (2014) 2.07
Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev (2005) 2.07
Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol (2005) 2.03
Nocardia veterana as a pathogen in North American patients. J Clin Microbiol (2003) 2.03
Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr (2004) 2.01
Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet (2005) 1.99
The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99
Prospects for new antitubercular drugs. Curr Opin Microbiol (2004) 1.94
Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med (2014) 1.94
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood (2013) 1.93
Hyper-IgE syndromes. Immunol Rev (2005) 1.92
Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis (2009) 1.91
Inborn errors of human JAKs and STATs. Immunity (2012) 1.90
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica (2011) 1.89
Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res (2003) 1.86
Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol (2002) 1.86
Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis (2010) 1.84
Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis (2003) 1.79
Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity. J Infect Dis (2006) 1.79
Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res (2007) 1.77
Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood (2011) 1.76
Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc (2014) 1.76